NCT07497646Completed
Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache
Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy of repeated bilateral greater occipital nerve (GON) blockade in patients with chronic migraine and chronic tension-type headache. Greater occipital nerve blockade has been widely used as an interventional treatment for chronic headache disorders; however, evidence regarding its differential efficacy across chronic headache phenotypes remains limited. Participants diagnosed with chronic migraine or chronic tension-type headache according to the International Headache Society criteria were randomized to receive bilateral GON blockade with 0.5% bupivacaine or placebo (0.9% saline). Injections were administered weekly during the first month and monthly during the following two months, resulting in a total of six injections over a three-month treatment period. The primary outcome measure is the change in monthly headache frequency from baseline to Month 1. Secondary outcomes include changes in headache intensity, headache duration, disability scores, and other clinical headache parameters during follow-up.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 290 (actual)
- First submitted
- 12 Mar 2026
- Start date
- 1 Jan 2025
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Saglik Bilimleri Universitesi
- Diseases
- Migraine
- NCT number
- NCT07497646
What you commit to
- Study type: Interventional
- Participants enrolled: 290
- From 1 Jan 2025 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous greater occipital nerve blockade within the last 3 months
- Participation in another clinical trial within the previous 30 days
Other illness
- Secondary headache disorders
- Known allergy or contraindication to bupivacaine
- Local infection at the injection site
- Coagulation disorders or ongoing anticoagulant therapy that contraindicates injection procedures
- Severe uncontrolled systemic disease
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Adults 18 years or older
- Diagnosis of chronic migraine or chronic tension-type headache according to International Classification of Headache Disorders (ICHD-3) criteria
- History of headache for at least 3 months prior to enrollment
- Ability to provide written informed consent
- Willingness to comply with study procedures and follow-up visits
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sultan Abdulhamid Han Research and Training Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.